Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

Sponsor
Chinese University of Hong Kong
Study ID
NCT02875132
Phase
PHASE2
Status
Completed

Conditions

  • Acral Lentiginous Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • pembrolizumab — DRUG
    pembrolizumab at 200mg IV infusion every 3 weeks

Study Details

To determine the Overall Response Rate (ORR), as defined as rate of complete response (CR) and partial response (PR) as per RECIST 1.1 in biological treatment-naïve patients with acral lentiginous melanoma treated with pembrolizumab

Key Dates

Start date
Feb 15, 2017
Status verified
Apr 2025
Primary completion
Feb 28, 2022
Completion
Feb 28, 2022

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: pembrolizumab

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: 2 years ]

Related coverage on Hipa.ai

Related Studies